Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects With Moderate to Severe Atopic Dermatitis.

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects With Moderate to Severe Atopic Dermatitis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2018

At a glance

  • Drugs GBR 830 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms OXFORAD
  • Sponsors Glenmark Pharmaceuticals Ltd

    • Most Recent Events

    • 16 Apr 2018 According to a Glenmark Pharmaceuticals media release, enrollment is expected to begin in June 2018.
    • 16 Apr 2018 Status changed from planning to recruiting, according to a Glenmark Pharmaceuticals media release.
    • 04 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top